Missouri 2024 Regular Session

Missouri Senate Bill SB956 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2	EXPLANATION-Matter enclosed in bold-faced brackets [thus] in this bill is not enacted
3	3	and is intended to be omitted in the law.
4	4	SECOND REGULAR SESSION
5	5	SENATE BILL NO. 956
6	6	102ND GENERAL ASSEMBLY
7	7	INTRODUCED BY SENATOR ESLINGER.
8	8	3503S.01I KRISTINA MARTIN, Secretary
9	9	AN ACT
10	10	To repeal section 336.010, RSMo, and to enact in lieu thereof one new section relating to the
11	11	practice of optometry.
12	12
13	13	Be it enacted by the General Assembly of the State of Missouri, as follows:
14	14	Section A. Section 336.010, RSMo, is repealed and one new 1
15	15	section enacted in lieu thereof, to be known as section 336.010, 2
16	16	to read as follows:3
17	17	336.010. 1. The "practice of optometry" is the 1
18	18	examination, diagnosis, [treatment, and preventative care ] 2
19	19	prevention, and treatment, surgical or nonsurgical, of the 3
20	20	eye, adnexa, and vision. The practice includes, but is not 4
21	21	limited to: 5
22	22	(1) The examination of the eye, a dnexa, and vision to 6
23	23	determine the accommodative and refractive states, visual 7
24	24	perception, conditions, and diseases; 8
25	25	(2) The diagnosis and treatment of conditions or 9
26	26	diseases of the eye, adnexa, and vision; 10
27	27	(3) The performance of diagnostic procedures and 11
28	28	ordering of laboratory and imaging tests for the diagnosis 12
29	29	of vision and conditions and diseases of the eye and adnexa; 13
30	30	(4) The prescription and administration of 14
31	31	pharmaceutical agents [, excluding injectable agents, ] for 15
32	32	the purpose of examination, diagnosis, and treatment of 16
33	33	vision and conditions or diseases of the eye and adnexa; 17 SB 956 2
34	34	(5) The removal of superficial foreign bodies from the 18
35	35	eye or adnexa; 19
36	36	(6) Notwithstanding the provisions of any other law to 20
37	37	the contrary, including section 334.010, the correction and 21
38	38	relief of ocular abnormalities by surgical procedures not 22
39	39	excluded under subsection 2 of this section; 23
40	40	(7) The employment of objective or subjective 24
41	41	mechanical means to determine the accommodative or 25
42	42	refractive states of the human eye; 26
43	43	[(7)] (8) The prescription or adaptation of lenses, 27
44	44	prisms, devices, or ocular exercises to correct defects or 28
45	45	abnormal conditions of the human eye or vision or to adjust 29
46	46	the human eye to special conditions; 30
47	47	[(8)] (9) The prescription and fitting of ophthalmic 31
48	48	or contact lenses and devices; 32
49	49	[(9)] (10) The prescription and administration of 33
50	50	vision therapy; and 34
51	51	[(10)] (11) The prescription and administration of low 35
52	52	vision care. 36
53	53	2. An optometrist [may] shall not perform [surgery, 37
54	54	including the use of lasers for treatment of any disease or 38
55	55	condition or for the correction of refractive error ] the 39
56	56	following procedures, except for the preoperative and 40
57	57	postoperative care of these procedures : 41
58	58	(1) Retina laser procedures, laser -assisted in situ 42
59	59	keratomileusis (LASIK), and photorefractive keratectomy 43
60	60	(PRK); 44
61	61	(2) Nonlaser surgery related to removal of the eye 45
62	62	from a living human being; 46
63	63	(3) Nonlaser surgery requiring full thic kness incision 47
64	64	or excision of the cornea or sclera other than paracentesis 48 SB 956 3
65	65	in an emergency situation requiring immediate reduction of 49
66	66	the pressure inside the eye; 50
67	67	(4) Penetrating keratoplasty (corneal transplant) or 51
68	68	lamellar keratoplasty; 52
69	69	(5) Nonlaser surgery requiring incision of the iris 53
70	70	and ciliary body, including iris diathermy or cryotherapy; 54
71	71	(6) Nonlaser surgery requiring incision of the 55
72	72	vitreous; 56
73	73	(7) Nonlaser surgery requiring incision of the retina; 57
74	74	(8) Nonlaser surgical extraction of the crystalline 58
75	75	lens; 59
76	76	(9) Nonlaser surgical intraocular implants; 60
77	77	(10) Incisional or excisional nonlaser surgery of the 61
78	78	extraocular muscles; 62
79	79	(11) Nonlaser surgery of the eyelid for eyelid 63
80	80	malignancies or for incis ional cosmetic or mechanical repair 64
81	81	of blepharochalasis, ptosis, and tarsorrhaphy; 65
82	82	(12) Nonlaser surgery of the bony orbit, including 66
83	83	orbital implants; 67
84	84	(13) Incisional or excisional nonlaser surgery of the 68
85	85	lacrimal system other than lacrimal probing or related 69
86	86	procedures; 70
87	87	(14) Nonlaser surgery requiring full thickness 71
88	88	conjunctivoplasty with graft or flap; 72
89	89	(15) Any nonlaser surgical procedure that does not 73
90	90	provide for the correction and relief of ocular 74
91	91	abnormalities; 75
92	92	(16) Laser or nonlaser injection into the posterior 76
93	93	chamber of the eye to treat any macular or retinal disease; 77
94	94	and 78
95	95	(17) The administration of general anesthesia . 79 SB 956 4
96	96	3. As used in this chapter, except as the context may 80
97	97	otherwise require, the foll owing terms mean: 81
98	98	(1) "Eye", the human eye; 82
99	99	(2) "Adnexa", all structures adjacent to the eye and 83
100	100	the conjunctiva, lids, lashes, and lacrimal system; 84
101	101	(3) "Board", the Missouri state board of optometry; 85
102	102	(4) "Diagnostic pharmaceut ical agents", topically 86
103	103	applied pharmaceuticals used for the purpose of conducting 87
104	104	an examination of the eye, adnexa, and vision; 88
105	105	(5) "Low vision care", the examination, treatment, and 89
106	106	management of patients with visual impairments not treatable 90
107	107	by conventional eyewear or contact lenses and may include a 91
108	108	vision rehabilitation program to enhance remaining vision 92
109	109	skills; 93
110	110	(6) "Pharmaceutical agents", any diagnostic and 94
111	111	therapeutic drug or combination of drugs that assist the 95
112	112	diagnosis, prevention, treatment, or mitigation of abnormal 96
113	113	conditions or symptoms of the human eye, adnexa, and vision; 97
114	114	(7) "Therapeutic pharmaceutical agents", those 98
115	115	pharmaceuticals[, excluding injectable agents, ] used for the 99
116	116	treatment of conditions or dis eases of the eye, adnexa, and 100
117	117	vision; 101
118	118	(8) "Vision therapy", a treatment regiment to improve 102
119	119	a patient's diagnosed visual dysfunctions, prevent the 103
120	120	development of visual problems, or enhance visual 104
121	121	performance to meet the defined needs of the pat ient. 105
122	122	